Are you curious how transcranial magnetic stimulation (TMS) therapy moved from research labs into everyday depression care? Understanding the history of TMS therapy can help you feel more confident as you consider whether it belongs in your plan.
Early Lab Work and Foundational Studies (1980s–1990s)
In the 1980s and 1990s, researchers began using magnetic fields to stimulate targeted brain regions and observe effects on mood and cognition. Early experiments mapped cortical excitability and showed that brief, focused magnetic pulses could reliably activate specific brain regions through neurostimulation. Preliminary safety parameters, such as intensity and train duration limits, emerged from this work and guided later clinical research into TMS therapy.
From Parameters to Practice: Refining Technique (1990s–2000s)
Over the next decade, controlled studies refined parameters of neurostimulation therapy. Investigators standardized coil positioning using motor-threshold mapping and, in some centers, neuronavigation to improve consistency across sessions. Research also explored stimulation frequencies and schedules that produced cumulative, measurable changes on validated mood scales. This laid the groundwork for clinical use of TMS therapy.
2008 FDA Clearance: A Clinical Turning Point
In 2008, the first TMS device received FDA-cleared status for the treatment of major depressive disorder in adults whose symptoms had not improved with medication. Randomized, sham-controlled trials supported the decision. This milestone marked the moment when a neuroscience tool became a practical option in outpatient behavioral health settings. It also enabled structured training, clinical protocols, and billing pathways, allowing outpatient practices to offer non-invasive, device-based care.
Scaling Up: Devices, Workflows, and Real-World Tracking
Since then, device engineering, treatment workflows, and outcome tracking have matured, with NeuroStar TMS systems participating in more than 65 studies and delivering millions of treatments. Moreover, large registries and quality-improvement programs now capture outcomes, safety events, and patient-reported measures at scale, informing everyday practice and refining precise targeting, patient comfort, and consistent measurement across the full course of treatment.
Evidence and Real-World Outcomes
Large datasets now help set expectations for neurostimulation of the brain. In a real-world outcomes registry, NeuroStar TMS was associated with improvement in 83 percent of patients, demonstrating meaningful symptom change across diverse practices and patient profiles (Sackeim HA, et al. (2020). J Affective Disorders, 277(12):65-74). Results usually build over four to six weeks, and benefits can last up to 12 months, which informs how we discuss follow-up and reassessment (Dunner DL, et al. (2014). J Clin Psychiatry, 75(12):1394-1401).
How Today’s NeuroStar TMS Fits Into Care
Modern NeuroStar TMS uses precisely delivered magnetic pulses, similar to the technology found in MRI environments, focused on mood-related brain circuits to provide care. There is no systemic medication exposure, no anesthesia, and you remain awake during sessions. There is a moderate risk of side effects, which may include temporary scalp discomfort or headache around treatment times. For obsessive-compulsive disorder, TMS is an adjunct treatment, meaning patients should continue other therapies they are using.
Call Us Today To Explore NeuroStar’s TMS History and How Treatment May Work for You
Understanding the history of TMS therapy, from early research to today’s FDA-cleared NeuroStar TMS, can help you decide whether it is right for you. If you want a clear, evidence-informed view of your options, we are ready to help you compare paths and decide what aligns with your goals. Contact us today to schedule a conversation about whether TMS therapy could fit your plan.
